Senseonics (NYSE:SENS) announced today that it entered into a definitive agreement to offer $16 million in common stock. Germantown, Maryland-based Senseonics plans to offer more than 45.7 million shares of common stock. It priced the shares at 35¢ per share in a registered direct offering. In a concurrent private placement, the company agreed to issue […]
Senseonics
Senseonics, Ascensia launch Eversense 365 year-long CGM in the U.S.
Ascensia Diabetes Care announced today that it launched the Eversense 365 CGM system from Senseonics (NYSE:SENS) in the U.S. Eversense 365, an implantable continuous glucose monitor (CGM), is indicated for people with type 1 and type 2 diabetes aged 18 years and older. Senseonics announced last month that it received FDA clearance for Eversense 365. With […]
Senseonics wins FDA nod for 365-day implantable CGM
Senseonics (NYSE:SENS) announced today that it received FDA clearance for its next-generation Eversense 365 CGM system. Eversense 365, an implantable continuous glucose monitor (CGM), becomes the world’s first 365-day CGM system, according to the company. Its indications cover people with type 1 and type 2 diabetes aged 18 years and older. The system also received clearance […]
The 9 largest diabetes technology companies in the world
Diabetes technology comes in all shapes and sizes: insulin delivery systems, continuous glucose monitors and more. The companies that develop these technologies come in all shapes and sizes, too. Some focus entirely (or almost entirely) on solutions for people with diabetes. Others are much larger medtech firms that still have sizable business units that focus […]
Senseonics misses Q2 sales expectations but 365-day CGM is on track for Q4 launch
Senseonics (NYSE:SENS) shares dipped after hours today on second-quarter results that missed the consensus sales forecast. Shares of SENS fell 4% to 39¢ apiece in post-market trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the day up nearly 1%. The Germantown, Maryland-based long-term implantable […]
The biggest stories from the American Diabetes Association (ADA) 2024 Scientific Sessions
The American Diabetes Association took to Orlando, Florida, the past few days for its 84th Scientific Sessions as optimism grows over diabetes tech. Topics covered included expanding technologies to the type 2 diabetes population (90% of people with diabetes), GLP-1 drugs, automation, broadening user bases and more. The usual big-hitters stepped up to the plate […]
The steps ahead for the Eversense implantable CGM platform
As Senseonics and Ascensia Diabetes Care looked for someone to help scale their CGM business, they turned to someone had only just retired. After close to eight years as Tandem Diabetes Care CCO, Brian Hansen notified the company of his decision to step down last August. His final day landed on Dec. 31, but he […]
Senseonics expects a Q4 launch for 365-day CGM, offers full-year outlook
Senseonics (NYSE:SENS) today shared its full-year financial outlook and laid out expectations for a new product launch this year. The Germantown, Maryland-based company said the FDA review of its next-generation, 365-day, once-per-week calibration Eversense implantable continuous glucose monitor (CGM) is advancing as planned. It expects the progress to enable 510(k) clearance in the near future […]
Senseonics posts Q1 sales beat, submits 365-day iCGM to FDA
Senseonics (NYSE:SENS) shares ticked up after the market closed today on first-quarter results that came in ahead of the consensus sales forecast. Shares of SENS rose 8.1% to 41¢ apiece in post-market trading today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down slightly. […]
Senseonics, Rimidi partner on remote diabetes monitoring program
Senseonics (NYSE:SENS) announced today that it entered into a strategic partnership with Rimidi to develop a remote patient monitoring program. Rimidi develops clinical management platforms for optimizing workflows, enhance patient experiences and hit objectives for chronic disease management. Together, the companies aim to develop the Eversense remote patient monitoring (RPM) program for use by healthcare […]